Information Provided By: 
Fly News Breaks for March 1, 2019
BIO
Mar 1, 2019 | 07:37 EDT
Barclays analyst Jack Meehan raised his price target for Bio-Rad Laboratories to $340 saying the company's Q4 results "hit all the important marks." The analyst views the initial 2019 guidance as better than expected and continues to believe that Bio-Rad has "substantial long-term opportunity ahead." He also thinks the stock's current valuation is "compelling" and reiterates an Overweight rating on the name.
News For BIO From the Last 2 Days
There are no results for your query BIO
